Charles Erlichman
Impact in
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- Cancer-related Molecular Pathways
- Cancer Treatment and Pharmacology
- Pancreatic and Hepatic Oncology Research
- Pathology and Forensic Medicine top 0.5%
Papers in
- Oncology 136
- Colorectal Cancer Treatments and Studies 51
- Cancer Treatment and Pharmacology 43
-
- Cancer therapeutics and mechanisms 28
- PI3K/AKT/mTOR signaling in cancer 23
- Heat shock proteins research 18
- Co-authors
- Shai Fine (11 shared papers)Alex A. Adjei (45 shared papers)Henry C. Pitot (45 shared papers)Scott H. Kaufmann (36 shared papers)Matthew M. Ames (27 shared papers)T Elhakim (4 shared papers)Joel Picus (22 shared papers)Michelle R. Mahoney (11 shared papers)
- Journals
- Journal of Clinical Oncology (85 papers)Cancer Chemotherapy and Pharmacology (18 papers)Investigational New Drugs (18 papers)Cancer Research (12 papers)Clinical Cancer Research (12 papers)
- Partner nations
- United StatesCanadaSingapore
In The Last Decade
Charles Erlichman
309 papers receiving 11.7k citations
Peers
Comparison fields: 5 of 139
- Oncology 4.9k
- Pathology and Forensic Medicine 1.5k
- Cancer Research 1.0k
- Molecular Biology 4.6k
- Hepatology 464
Countries citing papers authored by Charles Erlichman
This map shows the geographic impact of Charles Erlichman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Erlichman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Erlichman more than expected).
Fields of papers citing papers by Charles Erlichman
This network shows the impact of papers produced by Charles Erlichman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Erlichman. The network helps show where Charles Erlichman may publish in the future.
Co-authors
The 25 scholars most cited alongside Charles Erlichman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 313 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1988 | 408 | |
| 2 | 2005 | 354 | |
| 3 | 2010 | 330 | |
| 4 | 1998 | 289 | |
| 5 | 1988 | 278 | |
| 6 | 2003 | 271 | |
| 7 | 2005 | 266 | |
| 8 | 2009 | 263 | |
| 9 | 2006 | 257 | |
| 10 | 1991 | 212 | |
| 11 | 2010 | 210 | |
| 12 | 2014 | 201 | |
| 13 | A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. | 2000 | 200 |
| 14 | The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. | 2001 | 174 |
| 15 | 2003 | 168 | |
| 16 | 2006 | 164 | |
| 17 | 2008 | 154 | |
| 18 | 2006 | 146 | |
| 19 | 2009 | 142 | |
| 20 | 2012 | 137 |
About Charles Erlichman
Charles Erlichman is a scholar working on Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Surgery, having authored 313 papers that have together received 12.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (51 papers), Cancer Treatment and Pharmacology (43 papers), Cancer therapeutics and mechanisms (28 papers), PI3K/AKT/mTOR signaling in cancer (23 papers), Lung Cancer Treatments and Mutations (19 papers), Heat shock proteins research (18 papers), Neuroendocrine Tumor Research Advances (17 papers) and Chronic Lymphocytic Leukemia Research (16 papers). The work is most often cited by research in Oncology (4.9k citations), Pathology and Forensic Medicine (1.5k citations), Cancer Research (1.0k citations), Molecular Biology (4.6k citations) and Hepatology (464 citations). Charles Erlichman has collaborated with scholars based in United States, Canada and Singapore. Frequent co-authors include Shai Fine, Alex A. Adjei, Henry C. Pitot, Scott H. Kaufmann, Matthew M. Ames, T Elhakim, Joel Picus, Michelle R. Mahoney, A. Wong and Tom R. Fitch. Their work appears in journals such as Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Investigational New Drugs, Cancer Research and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.